Approved comparison material connected to this topic.
5 total recordsSource comparisons are presented without a generated winner.
CJC-1295 alone GHRH receptor agonism, sustained baseline GH 1–2× weekly Moderate (20–40 ng/mL increase) Minimal Moderate Effective for maintaining GH floor but lacks pulsatile amplitude needed for robust anabo…
CJC-1295 Monotherapy 1–2mg weekly None 20–30% above baseline 16–20 weeks Provides baseline elevation but lacks pulsatile amplitude. Slower onset, modest results Ipamorelin Monotherapy 200–300mcg 1–2× daily 25–…
CJC-1295 Alone (2 mg/week) +120–180% 140–160 2.1–2.8 kg None measured Extends GH pulse duration but doesn't amplify magnitude. Effective for baseline optimization but limited hypertrophic stimulus Ipamorelin A…
CJC-1295 (with DAC) GHRH analog. Sustained growth hormone release 6–8 days Once weekly Baseline GH elevation for multi-day repair windows High (GHRH receptors only) Essential for protocols requiring sustained …
CJC-1295 Only 1–2mg weekly None Weekly Minimal (GH pulses occur but lack amplitude) 10–15% Insufficient for sleep optimization—GHRH alone doesn't trigger strong enough nocturnal pulses Ipamorelin Only 200–300m…